This roundtable series reviews the use of Bruton’s tyrosine kinase inhibition as front-line treatment for patients with chronic lymphocytic leukemia discussed in virtual live events.

Treating CLL With Bruton's Tyrosine Kinase Inhibitors

Choosing Between Venetoclax or BTK Inhibitors in Frontline CLL

February 14, 2022

During a live virtual event, Javier Pinilla-Ibarz, MD, PhD, discussed treatment options for chronic lymphocytic leukemia including ibrutinib, acalabrutinib, and venetoclax with obinutuzumab.

Part 2: Supporting Data for Ibrutinib-Based Regimens in Frontline CLL

December 22, 2021

During a live virtual event, Jose Sandoval Sus, MD, discussed with participating physicians frontline treatment options for patients with chronic lymphocytic leukemia, with questions by Targeted Oncology.

Part 1: Sandoval Sus Discusses Recommended Treatments for a Patient With CLL

December 13, 2021

During a live virtual event, Jose Sandoval Sus, MD, discussed with participating physicians frontline recommended treatment options for patients with chronic lymphocytic leukemia based on a case scenario, with questions by Targeted Oncology.

$Part 2: Venetoclax and PI3K Inhibition for Relapsed/Refractory CLL$

Part 2: Venetoclax and PI3K Inhibition for Relapsed/Refractory CLL

November 22, 2021

During a live virtual event, Danielle Brander, MD, discussed with participating physicians second-line treatment options for patients with chronic lymphocytic leukemia, with questions guided by Targeted Oncology.

Part 1: BTK Inhibitors for CLL in the Second Line

November 18, 2021

Part 3: Considerations for Venetoclax-Based Therapy in Frontline CLL

November 05, 2021

During a live virtual event, Sameer A. Parikh, MBBS, discussed with participating physicians frontline treatment options in patients with chronic lymphocytic leukemia.

Part 2: BTK Inhibitor Options for Frontline CLL

November 03, 2021

During a live virtual event, Sameer A. Parikh, MBBS, discussed with participating physicians frontline treatment options of BTK inhibitors in patients with chronic lymphocytic leukemia.

Part 1: Frontline Treatment Options for CLL by Risk

October 29, 2021

During a live virtual event, Sameer A. Parikh, MBBS, discussed with participating physicians the treatment options for patients with chronic lymphocytic leukemia in the front-line setting by risk assessment.